journal
https://read.qxmd.com/read/37178646/primary-retroperitoneal-sarcoma-a-comparison-of-survival-outcomes-in-specialist-and-non-specialist-sarcoma-centres
#21
JOURNAL ARTICLE
Fabio Tirotta, Andrew Bacon, Shane Collins, Anant Desai, Hanhua Liu, Lizz Paley, Dirk Strauss, Sandra J Strauss
BACKGROUND: Consensus guidelines outline that patients with primary retroperitoneal sarcoma (RPS) should be managed within specialist sarcoma centres (SSC). There is, however, a paucity of population-based data detailing incidence and outcomes in these patients. Hence, we aimed to evaluate patterns of care among RPS patients in England and compare outcomes for those undergoing surgery in high-volume specialist sarcoma centres (HV-SSC), low-volume SSC (LV-SSC), and non-SSC (N-SSC). METHODS: Data on patients diagnosed with primary RPS between 2013 and 2018 were extracted from NHS Digital's National Cancer Registration and Analysis Service using the national cancer registration dataset...
April 17, 2023: European Journal of Cancer
https://read.qxmd.com/read/37146505/sex-differences-in-treatment-allocation-and-survival-of-potentially-curable-gastroesophageal-cancer-a-population-based-study
#22
JOURNAL ARTICLE
Marianne C Kalff, Willemieke P M Dijksterhuis, Anna D Wagner, Sabine Oertelt-Prigione, Rob H A Verhoeven, Valery E P P Lemmens, Hanneke W M van Laarhoven, Suzanne S Gisbertz, Mark I van Berge Henegouwen
BACKGROUND: Although curative treatment options are identical for male and female gastroesophageal cancer patients, access to care and survival may vary. This study aimed to compare treatment allocation and survival between male and female patients with potentially curable gastroesophageal cancer. METHODS: Nationwide cohort study including all patients with potentially curable gastroesophageal squamous cell or adenocarcinoma diagnosed between 2006 and 2018 registered in the Netherlands Cancer Registry...
April 8, 2023: European Journal of Cancer
https://read.qxmd.com/read/37142539/landscape-of-neoadjuvant-therapy-in-her2-positive-breast-cancer-a-systematic-review-and-network-meta-analysis
#23
JOURNAL ARTICLE
Guillermo Villacampa, Alexios Matikas, Mafalda Oliveira, Aleix Prat, Tomás Pascual, Andri Papakonstantinou
BACKGROUND: The recommended preoperative approach for HER2-positive breast cancer is unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen and ii) whether anthracyclines could be excluded. METHODS: A systematic literature search in Medline, Embase and Web of Science databases was performed. Studies had to satisfy the following criteria: i) randomised controlled trials (RCTs), ii) enroled patients treated preoperatively for HER2-positive BC (breast cancer), iii) at least one treatment group received an anti-HER2 agent, iv) available information of any efficacy end-point and v) published in English...
April 8, 2023: European Journal of Cancer
https://read.qxmd.com/read/37163806/the-sintart-2-study-a-phase-ii-non-randomised-controlled-trial-of-induction-chemotherapy-photon-proton-and-carbon-ion-based-radiotherapy-integration-in-patients-with-locally-advanced-unresectable-sinonasal-tumours
#24
JOURNAL ARTICLE
Paolo Bossi, Ester Orlandi, Carlo Resteghini, Barbara Vischioni, Piero Nicolai, Paolo Castelnuovo, Simone Gambazza, Laura D Locati, Mario Turri-Zanoni, Marco Ferrari, Nadia Facchinetti, Nicola A Iacovelli, Giuseppina Calareso, Pasquale Quattrone, Anna Cavallo, Alessandro Tuzi, Lisa Licitra
PURPOSE: Unresectable, locally advanced sinonasal epithelial tumours are rare diseases with poor prognosis. Multimodal approach is widely used, although no standard therapy has been established in prospective trials. This study assessed activity and safety of an innovative integration of multimodality treatment-induction chemotherapy (ICT), surgery and radiotherapy (RT)-modulated by histology and response to ICT. METHODS: Patients with untreated, unresectable sinonasal epithelial tumours with selected histotypes (squamous cell carcinoma, intestinal-type adenocarcinoma, sinonasal undifferentiated and neuroendocrine carcinoma, olfactory neuroblastoma) were enroled in a single-arm, open-label, phase II, multicentre clinical trial...
April 7, 2023: European Journal of Cancer
https://read.qxmd.com/read/37149961/hydrocortisone-to-reduce-dexamethasone-induced-neurobehavioral-side-effects-in-children-with-acute-lymphoblastic-leukaemia-results-of-a-double-blind-randomised-controlled-trial-with-cross-over-design
#25
JOURNAL ARTICLE
Annelienke M van Hulst, Erica L T van den Akker, Emma J Verwaaijen, Marta Fiocco, Niki Rensen, Raphaële R L van Litsenburg, Saskia M F Pluijm, C Michel Zwaan, Hanneke M van Santen, Rob Pieters, Andrea W M Evers, Martha A Grootenhuis, Marry M van den Heuvel-Eibrink
BACKGROUND: Dexamethasone is a cornerstone of paediatric acute lymphoblastic leukaemia (ALL) treatment, although it can induce serious side-effects. Our previous study suggests that children who suffer most from neurobehavioural side-effects might benefit from physiological hydrocortisone in addition to dexamethasone treatment. This study aimed to validate this finding. METHODS: Our phase three, double-blind, randomised controlled trial with cross-over design included ALL patients (3-18 years) during medium-risk maintenance therapy in a national tertiary hospital between 17th May 2018 and 5th August 2020...
April 7, 2023: European Journal of Cancer
https://read.qxmd.com/read/37137204/do-more-targets-allow-more-cancer-treatments-or-not
#26
JOURNAL ARTICLE
Paolo Marchetti, Giuseppe Curigliano, Silvia Calabria, Carlo Piccinni, Andrea Botticelli, Nello Martini
The three current oncology models (histological, agnostic and mutational) mainly differ in clinical, technological and organisational aspects, leading to different regulatory procedures and implications in antineoplastic therapy access by patients. Within the histological and agnostic models, Regulatory Agencies authorise target therapies and define their price, reimbursement, prescription and access based on results from clinical trials including patients affected by the same tumour (histological) or subjects with specific genetic mutations regardless of the tumour site or the histology (agnostic)...
April 7, 2023: European Journal of Cancer
https://read.qxmd.com/read/37167762/shining-a-light-on-myeloid-cell-targeted-immunotherapy
#27
REVIEW
Casey W Shuptrine, Vincent M Perez, Sara R Selitsky, Taylor H Schreiber, George Fromm
Despite over a decade of clinical trials combining inhibition of emerging checkpoints with a PD-1/L1 inhibitor backbone, meaningful survival benefits have not been shown in PD-1/L1 inhibitor resistant or refractory solid tumours, particularly tumours dominated by a myelosuppressive microenvironment. Achieving durable anti-tumour immunity will therefore likely require combination of adaptive and innate immune stimulation, myeloid repolarisation, enhanced APC activation and antigen processing/presentation, lifting of the CD47/SIRPα (Cluster of Differentiation 47/signal regulatory protein alpha) 'do not eat me' signal, provision of an apoptotic 'pro-eat me' or 'find me' signal, and blockade of immune checkpoints...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37164774/the-sintart-1-study-a-phase-ii-non-randomised-controlled-trial-of-induction-chemotherapy-surgery-photon-proton-%C3%A2-and-carbon-ion-based-radiotherapy-integration-in-patients-with-locally-advanced-resectable-sinonasal-tumours
#28
JOURNAL ARTICLE
Carlo Resteghini, Paolo Castelnuovo, Piero Nicolai, Ester Orlandi, Paolo Bossi, Barbara Vischioni, Alberto Schreiber, Simone Gambazza, Nicola Alessandro Iacovelli, Paolo Battaglia, Marco Guzzo, Mario Turri-Zanoni, Davide Mattavelli, Nadia Facchinetti, Giuseppina Calareso, Marco Ravanelli, Carla Facco, Tiziana Tartaro, Lisa Licitra
PURPOSE: Sinonasal tumours are rare diseases with poor prognosis. Multimodal approach including surgery is widely used, although no standard therapy has been established in prospective trials. This study assessed activity and safety of an innovative integration of multimodality treatment-induction chemotherapy (ICT), surgery and radiotherapy (RT)-modulated by histology and response to ICT. METHODS: Patients with untreated, operable sinonasal tumours with selected histotypes (squamous cell carcinoma, intestinal-type adenocarcinoma, sinonasal undifferentiated and neuroendocrine carcinoma, olfactory neuroblastoma) were enrolled in a single-arm, phase II, multicenter clinical trial...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37130464/mental-health-outcomes-in-older-breast-cancer-survivors-five-year-follow-up-from-the-climb-study
#29
JOURNAL ARTICLE
Annelieke A Lemij, Nienke A de Glas, Marloes G M Derks, Eugenie M H Linthorst-Niers, Onno R Guicherit, Carmen C van der Pol, Titia E Lans, Thijs van Dalen, Annelie J E Vulink, Jos W S Merkus, Leander van Gerven, Frederiek van den Bos, Nathaly Rius Ottenheim, Gerrit-Jan Liefers, Johanneke E A Portielje
BACKGROUND: There is a lack of information on mental health outcomes for the increasing older population. Therefore, the aim of the current study is to assess depressive symptoms, loneliness, and apathy in older patients with breast cancer within the first 5 years after diagnosis. METHODS: Women aged ≥70 years with early-stage breast cancer were included. Multivariate linear mixed models were used to assess longitudinal changes in symptoms of depression (according to the 15-item Geriatric Depression Scale), loneliness (according to the De Jong Gierveld Loneliness Scale) and apathy (according to the Starkstein Apathy Scale) over time at 3, 9, 15, 27 and 60 months follow-up...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37130463/cytoreductive-surgery-for-advanced-epithelial-ovarian-cancer-in-the-poly-adp-ribose-polymerase-inhibitors-era-is-it-time-for-a-new-paradigm-shift-a-systematic-review-and-meta-analysis
#30
REVIEW
Inge T A Peters, Claudia Marchetti, Antonella De Palma, Diana Giannarelli, Antonella Carcagnì, Giovanni Scambia, Anna Fagotti
INTRODUCTION: In patients with newly diagnosed advanced high-grade serous and endometrioid epithelial ovarian cancer (EOC) first-line maintenance therapy with poly(ADP-ribose) polymerase inhibitors (PARPi) tremendously improved progression-free survival (PFS). Yet, data on the effect of PARPi in proportion to postoperative residual disease status were lacking. MATERIAL AND METHODS: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items of Systematic reviews and Meta-Analysis (PRISMA) guidelines...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37119639/a-prospective-multicentre-trial-on-survival-after-microwave-ablation-versus-resection-for-resectable-colorectal-liver-metastases-maverric
#31
JOURNAL ARTICLE
Pascale Tinguely, Simeon J S Ruiter, Jennie Engstrand, Robbert J de Haas, Henrik Nilsson, Daniel Candinas, Koert P de Jong, Jacob Freedman
AIM: This multi-centre prospective cohort study aimed to investigate non-inferiority in patients' overall survival when treating potentially resectable colorectal cancer liver metastasis (CRLM) with stereotactic microwave ablation (SMWA) as opposed to hepatic resection (HR). METHODS: Patients with no more than 5 CRLM no larger than 30 mm, deemed eligible for both SMWA and hepatic resection at the local multidisciplinary team meetings, were deliberately treated with SMWA (study group)...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37116288/neo-adjuvant-immunotherapies-bladder-cancer-as-a-platform-for-drug-development-targeting-mucosal-immunity
#32
JOURNAL ARTICLE
Rainjade Chung, James McKiernan, Nicholas Arpaia, Aurélien Marabelle, Mathieu Rouanne
Bacillus Calmette-Guerin (BCG) is a live attenuated Mycobacterium bovis strain, originally developed as a vaccine against tuberculosis. It is also the only bacterial cancer therapy approved by the US Food & Drug Administration for clinical use. BCG is delivered in the bladder, shortly after tumour resection, for patients with high-risk non-muscle invasive bladder cancer (NMIBC). Modulating mucosal immunity by exposing the urothelium to intravesical BCG has been the main therapeutic strategy for high-risk NMIBC over the last three decades...
April 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37098294/clinical-histopathological-and-molecular-features-of-dedifferentiated-melanomas-an-eortc-melanoma-group-retrospective-analysis
#33
JOURNAL ARTICLE
Juergen Hench, Daniela Mihic-Probst, Abbas Agaimy, Stephan Frank, Peter Meyer, Claus Hultschig, Sara Simi, Lucia Alos, Thiagarajah Balamurugan, Willeke Blokx, Francesca Bosisio, Rocco Cappellesso, Klaus Griewank, Eva Hadaschik, Leon C van Kempen, Werner Kempf, Maria Lentini, Luca Mazzucchelli, Gaetana Rinaldi, Piotr Rutkowski, Dirk Schadendorf, Bastian Schilling, Anna Szumera-Cieckiewicz, Joost van den Oord, Mario Mandalà, Daniela Massi
PURPOSE: Dedifferentiated melanoma (DedM) poses significant diagnostic challenges. We aimed to investigate the clinical, histopathological and molecular features of DedM. Methylation signature (MS) and copy number profiling (CNP) were carried out in a subgroup of cases. PATIENTS AND METHODS: A retrospective series of 78 DedM tissue samples from 61 patients retrieved from EORTC (European Organisation for Research and Treatment of Cancer) Melanoma Group centres were centrally reviewed...
April 2, 2023: European Journal of Cancer
https://read.qxmd.com/read/37146504/european-society-of-breast-cancer-specialists-advanced-breast-cancer-global-alliance-quality-indicators-for-metastatic-breast-cancer-care
#34
JOURNAL ARTICLE
Fatima Cardoso, Amelia McCartney, Antonio Ponti, Lorenza Marotti, Conny Vrieling, Alexandru Eniu, Berta Sousa, Carla Ripamonti, Luzia Travado, Sabine Spitz, Eva Jolly, Giuseppe Curigliano, Frederique Penault-Llorca, Frederic Lecouvet, Isabel T Rubio, Laura Biganzoli
AIMS: Improvement in the care of patients with metastatic breast cancer (MBC) can only occur if the adequate quality of care is implemented and verified, including access to multidisciplinary, specialised care given in accordance with high-quality guidelines. To this purpose, European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance joined efforts to develop the first set of quality indicators (QI) specifically for MBC that should be routinely measured and evaluated to ensure that breast cancer centres meet the required standards...
March 31, 2023: European Journal of Cancer
https://read.qxmd.com/read/37099945/tumour-mutational-burden-as-a-biomarker-in-patients-with-mismatch-repair-deficient-microsatellite-instability-high-metastatic-colorectal-cancer-treated-with-immune-checkpoint-inhibitors
#35
JOURNAL ARTICLE
Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Tumour mutational burden (TMB) is a promising biomarker for the prediction of treatment outcomes. PATIENTS AND METHODS: We screened 203 patients with dMMR/MSI-H mCRC treated with an anti-PD-(L)1 (anti-Programmed-Death-(Ligand)1) plus or minus an anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA-4) agent at three Italian Academic Centers...
March 31, 2023: European Journal of Cancer
https://read.qxmd.com/read/37167765/current-practice-of-genomic-profiling-of-patients-with-advanced-solid-tumours-in-italy-the-italian-register-of-actionable-mutations-rational-study
#36
JOURNAL ARTICLE
Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, Alessandro Morabito, Michele Milella, Fabrizio Tabbò, Giuseppe Curigliano, Cristina Masini, Paolo Marchetti, Giancarlo Pruneri, Valentina Guarneri, Giovanni L Frassineti, Gianpiero Fasola, Vincenzo Adamo, Bruno Daniele, Rossana Berardi, Florinda Feroce, Evaristo Maiello, Carmine Pinto
BACKGROUND: The Italian Register of Actionable Mutations (RATIONAL) is a multicentric, observational study collecting next-generation sequencing (NGS)-based tumour profiling data of patients with advanced solid tumours. METHODS: The study enrols patients who had available an NGS-based tumour profiling (Pathway-A) or undergo comprehensive genomic profiling (CGP) with FoundationOne CDx assays within the trial (Pathway-B). The primary endpoint was the rate of actionable mutations identified...
March 30, 2023: European Journal of Cancer
https://read.qxmd.com/read/36996626/ineligible-for-transplant-but-eligible-for-intensive-quadruplet-therapy-the-value-of-add-on-trials-for-vulnerable-patient-populations
#37
LETTER
Ghulam Rehman Mohyuddin, Aaron M Goodman
No abstract text is available yet for this article.
March 28, 2023: European Journal of Cancer
https://read.qxmd.com/read/37116287/position-statement-on-the-management-of-the-immune-checkpoint-inhibitor-induced-colitis-via-multidisciplinary-modified-delphi-consensus
#38
JOURNAL ARTICLE
Valérie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crapé, Michael Somers, Anne Hoorens, Joris Dutré, Triana Lobatón
INTRODUCTION: The use of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has shown increased overall survival in a wide range of cancer types with the associated risk of developing severe immune-mediated adverse events, commonly involving the gastrointestinal tract. AIM: The aim of this position statement is to provide an updated practice advice to the gastroenterologists and oncologists on the diagnosis and management of ICI-induced gastrointestinal toxicity...
March 25, 2023: European Journal of Cancer
https://read.qxmd.com/read/37068406/survival-in-melanoma-in-the-nordic-countries-into-the-era-of-targeted-and-immunological-therapies
#39
JOURNAL ARTICLE
Filip Tichanek, Asta Försti, Akseli Hemminki, Otto Hemminki, Kari Hemminki
OBJECTIVES: Survival in melanoma has been increasing and the most recent interest is to observe the population-level impact of novel targeted therapies and immunotherapy. We analysed survival in melanoma from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) over a 50-years period (1971-2020). METHODS: Relative 1-5/1- and 5-year survival data were obtained from the NORDCAN database for the years 1971-2020. We estimated annual changes in survival rates and determined significant breaking points for trends...
March 24, 2023: European Journal of Cancer
https://read.qxmd.com/read/37062212/surgeon-proficiency-gain-and-survival-after-gastrectomy-for-gastric-adenocarcinoma-a-population-based-cohort-study
#40
JOURNAL ARTICLE
Johannes P U Asplund, Hugh A Mackenzie, Sheraz R Markar, Jesper H F Lagergren
OBJECTIVE: Quality of surgery is essential for survival in gastric adenocarcinoma, but studies examining surgeons' proficiency gain of gastrectomies are scarce. This study aimed to reveal potential proficiency gain curves for surgeons operating patients with gastric cancer. METHODS: Population-based cohort study of patients who underwent gastrectomy for gastric adenocarcinoma in Sweden between 2006 and 2015 with follow-up throughout 2020. Data were retrieved from national registries and medical records...
March 24, 2023: European Journal of Cancer
journal
journal
30413
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.